To evaluate the prognostic significance of PCSK9 in CRC patient survival and its relationship with KRAS mutation status, we examined PCSK9 expression using a tissue microarray consisting of 137 CRC patients with known APC and KRAS mutation status (Table S2). This evidence concerns the gene KRAS and colorectal carcinoma.